FIELD: biotechnology.
SUBSTANCE: present invention relates to biotechnology, in particular to novel multispecific activated antibodies which are capable of specifically binding to two or more different targets or epitopes under certain conditions. One of the antigen-binding fragments of the antibody according to the present invention binds specifically to EGFR, while the second one binds to a target interacting with an immune effector cell or epitope. Each of the antigen-binding fragments in the antibody according to the present invention is linked by a masking group which inhibits the binding of such a fragment to its target, and a cleavable group exposed to certain proteolytic enzymes.
EFFECT: invention can be used for various therapeutic, diagnostic and preventive purposes.
18 cl, 16 ex, 11 tbl, 23 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| MULTISPECIFIC ANTIBODIES, MULTISPECIFIC ACTIVATED ANTIBODIES AND METHODS OF THEIR APPLICATION | 2014 |
|
RU2727836C2 |
| ANTIBODIES BINDING TO CD3 | 2019 |
|
RU2810924C2 |
| ANTIBODIES BINDING TO CD3 | 2019 |
|
RU2832669C2 |
| OBTAINING MULTISPECIFIC MIXTURES OF ANTIBODIES AND METHODS OF USE THEREOF | 2018 |
|
RU2815826C2 |
| POLYPEPTIDE LINKER FOR PRODUCTION OF MULTI-SPECIFIC ANTIBODIES | 2018 |
|
RU2776302C2 |
| MULTISPECIFIC ANTIBODY WITH BINDING SPECIFICITY OF HUMAN IL-13 AND IL-17 | 2020 |
|
RU2827946C1 |
| ANTIBODIES TO CHELATED RADIONUCLIDES | 2019 |
|
RU2833233C2 |
| MULTI-SPECIFIC ANTIBODIES AND METHODS OF THEIR PRODUCTION AND USE | 2018 |
|
RU2811477C2 |
| ANTIBODY TO CD3 AND ITS PHARMACEUTICAL USE | 2019 |
|
RU2802272C2 |
| ENGINEERED MULTI-SPECIFIC ANTIBODIES AND OTHER MULTIMERIC PROTEINS WITH ASYMMETRIC MUTATIONS IN THE CH2-CH3 REGION | 2018 |
|
RU2804031C2 |
